Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

FDA Begins Withdrawal For Midodrine Three Years After It First Threatened To End Approval

This article was originally published in The Pink Sheet Daily

Executive Summary

With no confirmatory studies in sight, agency takes action 14 years after accelerated approval of Shire's hypotension drug ProAmatine, which has since gone generic.

You may also be interested in...



Amid Avastin Noise, Shire Quietly Awaits Word On ProAmatine Public Hearing

The jury is still out on whether Shire’s hypotension drug ProAmatine (midodrine) will be the focus of the same type of public hearing recently held on the fate of Avastin’s metastatic breast cancer claim.

Amid Avastin Noise, Shire Quietly Awaits Word On ProAmatine Public Hearing

The jury is still out on whether Shire’s hypotension drug ProAmatine (midodrine) will be the focus of the same type of public hearing recently held on the fate of Avastin’s metastatic breast cancer claim.

Mylotarg Pulled Off Market, But Pfizer Continues Search For Appropriate Population

After a futile confirmatory trial, Pfizer will review ongoing studies to see if they can be refined to indentify patients that could benefit from the drug, oncology VP Eagle says.

Related Content

Topics

UsernamePublicRestriction

Register

PS071041

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel